Condition: Breast Cancer · Neoplasm, Breast · Breast Diseases · Sponsor: Silesian Centre for Heart Diseases
Breast cancer is the most commonly cancer in women in the overall global population. According to the World Cancer Research Fund International, there were more than 2.25 million new cases of breast cancer in women in 2020. Although the modern treatment strategies, based on the complex care, which consists of surgery, radiotherapy, hormone therapy, and targeted chemotherapy directed at specific cancer molecules have substantially reduced the risk of death due to breast cancer, their wide adoption results in the wider prevalence of cardiotoxicity, defined as either symptomatic heart failure, or asymptomatic contractile dysfunction. The occurrence of cardiotoxicity induced by anti-cancer therapies is estimated at 5-15%, and its development is the primary cause of therapy termination, which significantly reduces the probability of the efficacy of treatment. Several attempts have been made to determine the efficacious preventive strategy, which could diminish the risk of cancer-therapy induced cardiotoxicity. The results of the prior studies indicated a trend towards lower risk of troponin elevation, or left ventricular contractile dysfunction with the introduction of drugs interfering with the renin-angiotensin-aldosterone (RAA) axis, which constitute the primary treatment modality in heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan, the novel therapeutic agent, has been demonstrated to significantly improve prognosis in patients with HFrEF. Prior retros…
This description comes directly from the study's public registry record.
Mateusz Tajstra, MD, PhD, Assoc Prof · +48323733860 · mateusztajstra@wp.pl
Lucyna Broja · +48323733853 · l.broja@sccs.pl
Always discuss trial participation with your own doctor first.
| Regional Cancer Centre in Opole | Opole, Opole Voivodeship, Poland | Recruiting |
| Maria Sklodowska-Curie Institute - Oncology Centre (MSCI), Gliwice Branch | Gliwice, Silesian Voivodeship, Poland | Recruiting |
| Silesian Center for Heart Diseases | Zabrze, Silesian Voivodeship, Poland | Active Not Recruiting |
| Holy Cross Cancer Centre, Cardio-Oncology Division | Kielce, Świętokrzyskie Voivodeship, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05465031